Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases

M Dong, BP Yan, JK Liao, YY Lam, GWK Yip… - Drug discovery today, 2010 - Elsevier
M Dong, BP Yan, JK Liao, YY Lam, GWK Yip, CM Yu
Drug discovery today, 2010Elsevier
The Rho/rho-kinase (ROCK) pathway has an important role in the pathogenesis of several
cardiovascular diseases. The activation of ROCK is involved in the regulation of vascular
tone, endothelial dysfunction, inflammation and remodeling. The inhibition of ROCK has a
beneficial effect in a variety of cardiovascular disorders. Evidence from animal models and
from clinical use of ROCK inhibitors, such as Y-27632, fasudil and statins (ie pleiotropic
effects), supports the hypothesis that ROCK is a potential therapeutic target. This review …
The Rho/rho-kinase (ROCK) pathway has an important role in the pathogenesis of several cardiovascular diseases. The activation of ROCK is involved in the regulation of vascular tone, endothelial dysfunction, inflammation and remodeling. The inhibition of ROCK has a beneficial effect in a variety of cardiovascular disorders. Evidence from animal models and from clinical use of ROCK inhibitors, such as Y-27632, fasudil and statins (i.e. pleiotropic effects), supports the hypothesis that ROCK is a potential therapeutic target. This review provides a current understanding of the role of ROCK pathway in the regulation of vascular function and the use of ROCK inhibitors in the treatment of cardiovascular disorders.
Elsevier